Summary of OrthoPediatrics FY Conference Call (December 04, 2025) Company Overview - **Company**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric orthopedic medical devices Key Points and Arguments Q3 Performance and Guidance Adjustments - Despite a decrease in guidance, the company reported a strong Q3 performance, with challenges primarily in capital sales and Latin America [4][5][6] - The 7D capital product, a navigation platform for spine surgery, had no completed orders in Q3, leading to a significant revenue impact of several million dollars [4][5] - The company has decided to remove 7D revenue from future guidance to provide clearer expectations for investors [6][10] Revenue Growth Components - The company anticipates a baseline growth rate of around 12%, focusing on predictable and high-margin components of the business, including T&D implants and OPSB [32][34] - The scoliosis implant business is expected to remain flat, while international agency sales, particularly in Europe and Australia, are showing strong growth [34] New Product Development - OrthoPediatrics is at the beginning of a new product launch cycle, with significant investments in novel product development expected to impact growth from 2026 onwards [37][38] - Key products include the PNP tibia and femur, which are rapidly growing, and the 3P system, which has received positive feedback and is expected to become a workhorse for the company's hip systems [40][47] Market Opportunities - The plating market is large, with estimates suggesting a collective opportunity exceeding $50 million [48] - The early onset scoliosis (EOS) market in the U.S. is estimated to be over $50 million, with significant potential for growth due to limited competition [88][91] Financial Outlook - The company expects a substantial increase in EBITDA in 2026, with projections indicating a growth rate of around 65% [105][108] - The restructuring efforts and a focus on profitability are expected to positively impact cash flow and operational efficiency [109] Strategic Focus - OrthoPediatrics aims to expand its clinic presence, aspiring to have clinics in every children's hospital in the U.S. and select international markets [104] - The company is focused on generating free cash flow and has limited set deployment to manage cash conversion cycles effectively [58][62] Challenges and Risks - There are theoretical risks associated with not achieving 7D sales, which could impact the spine business, but the company does not anticipate significant negative effects on its implant business [17][29] - The company is cautious about capital deployment for new product launches, ensuring that cash usage aligns with growth strategies [64][68] Additional Important Insights - The company is leveraging advanced technologies in its products, such as RF technology in the LE device, which enhances surgical precision and reduces complications [76][78] - OrthoPediatrics is differentiating itself by focusing on complex surgeries for pediatric patients, which are often overlooked by competitors [71][72] This summary encapsulates the critical insights from the OrthoPediatrics FY Conference Call, highlighting the company's performance, strategic direction, and market opportunities.

Core Viewpoint - OrthoPediatrics (KIDS) shares have increased by 12.9% in the past four weeks, closing at $19.09, with a potential upside of 26.5% based on Wall Street analysts' mean price target of $24.14 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $5.01, indicating variability among analysts [2] - The lowest estimate is $19.00, suggesting a slight decline of 0.5%, while the highest estimate is $34.00, indicating a potential surge of 78.1% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding KIDS' ability to report better earnings than previously predicted supports the potential upside [4] - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, enhancing the outlook for KIDS [11] - Over the last 30 days, one earnings estimate has increased, leading to a 4.3% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - KIDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While consensus price targets may not be reliable for predicting gains, they can provide a directional guide for potential price movements [14]

Summary of OrthoPediatrics Conference Call Company Overview - **Company Name**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric Orthopedics - **Focus**: Solely dedicated to pediatric orthopedic solutions, with no involvement in adult orthopedic products [2][3] Key Points and Arguments - **Market Impact**: OrthoPediatrics has helped a cumulative total of 1.3 million children, with a goal to assist over 150,000 children in 2025 and an objective to reach 1 million annually in the future [2][3] - **Unique Product Development**: The company has developed products specifically designed for pediatric patients, addressing unique clinical conditions such as curved bones, which differ significantly from adults [2][3] - **Market Size**: The global pediatric orthopedic market is estimated to be around $6 billion, with significant segments including trauma and deformity, scoliosis, specialty bracing, and enabling technology [5] - **Sales Strategy**: OrthoPediatrics focuses exclusively on children's hospitals in the U.S., which number approximately 300-400, avoiding adult hospitals entirely [5][6] - **Sales Force**: The company employs over 230 sales agents in the U.S. and sells products in over 75 countries, supported by an additional 200 individuals servicing those hospitals [4][5] Product Portfolio and Innovations - **Product Range**: The company has expanded its product offerings from 17 at the time of its IPO in 2017 to over 80 systems currently available [14][22] - **Recent Acquisitions**: Notable acquisitions include Firefly (navigation system for scoliosis), Appifix (internal brace for scoliosis), and Boston O&P (specialty braces and clinics) [9][10][18] - **New Technologies**: Introduction of innovative products such as the VertiGlide system for severe early-onset scoliosis and the DF2 Brace for hip dysplasia, which replaces traditional spica casts [16][17] Financial Performance - **Revenue Growth**: The company has consistently achieved over 20% annual growth, with a projected growth rate of 14% for 2025 [19][21] - **EBITDA Guidance**: For 2025, the company expects adjusted EBITDA between $15 million and $17 million, a significant increase from $8.5 million the previous year [21][22] - **Cash Flow Management**: OrthoPediatrics aims to achieve positive free cash flow in Q4 2025 and break-even in 2026, having reduced cash usage significantly from $40 million two years ago to an expected $20 million this year [23][24] Strategic Focus - **Clinical Education Commitment**: The company emphasizes the importance of clinical education, hosting over 300 training sessions annually for surgeons and clinicians [4][13] - **Market Expansion**: Plans to continue expanding both product offerings and clinic presence, with a focus on specialty bracing, which is projected to grow over 20% annually for the next three to five years [19][18] Conclusion - OrthoPediatrics is positioned as a leader in the pediatric orthopedic market, with a strong commitment to innovation, clinical education, and strategic growth through acquisitions and product development [22][24]

Summary of OrthoPediatrics Conference Call Company Overview - **Company**: OrthoPediatrics (NasdaqGM: KIDS) - **Focus**: Pediatric orthopedics, specifically in trauma deformity and OPSB (Orthotic and Prosthetic Services Business) - **Sales Contribution**: Trauma Deformity and OPSB account for approximately 75% of company sales [1][1] Key Financial Performance - **Q3 Performance**: Trauma Deformity sales increased by 17%, and OPSB sales rose over 20% [1][1] - **Sales Guidance**: The company lowered its full-year sales guidance due to temporary issues, not related to competition or market opportunity [20][20] - **Growth Rate**: The company aims for a baseline growth rate of 12%, with potential for higher growth in certain quarters [29][29] Product Innovation and Strategy - **New Product Launches**: Recent launches include PD HIP products aimed at addressing developmental dysplasia of the hip (DDH) [8][8] - **R&D Pipeline**: Plans to launch four new products next year, with an increasing number in subsequent years [9][9] - **Market Expansion**: The company is expanding its clinic presence, having already surpassed its goal of four new markets for 2025, reaching seven [13][13] Market Dynamics - **Total Addressable Market (TAM)**: The company identifies 80 target markets in the US, with plans to penetrate 27 of those [19][19] - **Competitive Landscape**: Disruption in larger orthopedic companies may provide opportunities for OrthoPediatrics to gain market share and attract talent [46][46] Challenges and Risks - **Sales Miss**: The company experienced a sales miss due to unpredictable capital sales, particularly with a navigation platform for pediatric spine surgery [21][21][22][22] - **Latin America Operations**: The company has pulled set sales from Brazil out of guidance due to complex market dynamics and cash flow concerns [42][42] Future Outlook - **Profitability Goals**: The company maintains confidence in achieving its 25% margin and profitability targets despite recent disruptions [63][63] - **Long-term Vision**: OrthoPediatrics aims to evolve into a broader pediatric healthcare company, exploring opportunities in other subspecialties beyond orthopedics [66][66][68][68] Additional Insights - **Procedure Trends**: Stable pediatric procedure volumes are expected to continue into Q4 and beyond [44][44] - **Innovation Cycle**: The company is in the early stages of a significant R&D cycle, with multiple product launches anticipated in the coming years [60][60] This summary encapsulates the key points discussed during the OrthoPediatrics conference call, highlighting the company's performance, strategic initiatives, market dynamics, and future outlook.

Core Insights - OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing (OPSB) portfolio with the launch of two new products: the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, bringing the total to 31 systems within the OPSB division [1][3] Product Development - The new PediHip™ products are designed for treating Developmental Dysplasia of the Hip (DDH) and for post-operative stabilization in pediatric patients aged three years and younger, enhancing treatment options for this condition [2] - The company emphasizes its commitment to organic new product development and collaboration with pediatric hip experts to advance care for children [3] Market Position - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [4] - The company distributes its products in the United States and over 70 countries, highlighting its global reach in the pediatric orthopedic market [4]

Core Viewpoint - OrthoPediatrics (KIDS) shows potential for significant upside, with a mean price target of $24.14 indicating a 41.9% increase from the current price of $17.01, supported by positive earnings estimate revisions [1][11]. Price Targets and Analyst Estimates - The mean price target consists of seven short-term estimates with a standard deviation of $5.01, suggesting variability among analysts; the lowest estimate is $19.00 (11.7% increase), while the highest is $34.00 (99.9% increase) [2][9]. - Analysts have shown increasing optimism regarding KIDS' earnings prospects, as indicated by a 4.3% increase in the Zacks Consensus Estimate over the past month, with no negative revisions [12][11]. Analyst Behavior and Price Target Reliability - There is skepticism regarding the reliability of analysts' price targets, as they may set overly optimistic targets due to business incentives, which can mislead investors [7][8]. - A low standard deviation in price targets indicates a high degree of agreement among analysts about the stock's price movement direction, which can serve as a starting point for further research [9][10]. Investment Ranking and Conclusion - KIDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]. - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does imply a positive direction for price movement [14].

Core Insights - OrthoPediatrics Corp. is focused on advancing pediatric orthopedics and will participate in three upcoming investor conferences [1][2] Group 1: Upcoming Events - The company will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, at 1:20 pm ET in a fireside chat format [1] - OrthoPediatrics will present at the Jeffries Global Healthcare Conference in London on November 18, 2025, at 12:00 pm ET [1] - The company will also engage in a fireside chat at the Piper 37 Annual Healthcare Conference on December 4, 2025, at 9:30 am ET [1] Group 2: Company Overview - Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [2] - The company markets over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [2] - OrthoPediatrics has a global sales organization focused exclusively on pediatric orthopedics, distributing products in the United States and over 70 countries worldwide [2]

Financial Performance - Net revenue for Q3 2025 was $61,250,000, representing a 12.3% increase from $54,573,000 in Q3 2024[15] - Gross profit for Q3 2025 was $45,274,000, up from $40,060,000 in Q3 2024, indicating a gross margin improvement[15] - Operating loss for Q3 2025 was $(9,428,000), compared to $(5,566,000) in Q3 2024, reflecting increased operating expenses[15] - The company reported a net loss of $(11,773,000) for Q3 2025, compared to $(7,919,000) in Q3 2024[17] - For the nine months ended September 30, 2025, the net loss was $29,545,000, compared to a net loss of $21,753,000 for the same period in 2024, representing an increase in losses of approximately 35.5%[24] - Product sales for the three months ended September 30, 2025, totaled $61,250, an increase from $54,573 in 2024, representing a growth of 30.8%[103] - U.S. product sales for the nine months ended September 30, 2025, were $137,757, up from $118,269 in 2024, reflecting a growth of 16.5%[103] Assets and Liabilities - Total current assets increased to $245,852,000 as of September 30, 2025, from $237,173,000 at the end of 2024[13] - Total assets grew to $493,486,000 as of September 30, 2025, compared to $473,209,000 at December 31, 2024[13] - Total liabilities rose to $144,177,000 as of September 30, 2025, compared to $118,643,000 at December 31, 2024[13] - The accumulated deficit increased to $(265,109,000) as of September 30, 2025, from $(235,564,000) at the end of 2024[13] - The company’s cash position decreased to $16,826,000 as of September 30, 2025, from $43,820,000 at the end of 2024[13] Cash Flow - The company reported cash used in operating activities of $15,199,000 for the nine months ended September 30, 2025, a decrease from $23,061,000 in the same period of 2024[24] - Cash, cash equivalents, and restricted cash at the end of the period were $18,884,000, down from $45,777,000 at the beginning of the year[24] - Net cash used in investing activities increased to $36.4 million for the nine months ended September 30, 2025, compared to $10.8 million for the same period in 2024[151] - Net cash provided by financing activities was $24.4 million for the nine months ended September 30, 2025, compared to $53.7 million for the same period in 2024[152] Expenses - Research and development expenses for Q3 2025 were $2,333,000, down from $2,577,000 in Q3 2024[15] - Sales and marketing expenses increased by $1.9 million, or 11%, to $18.7 million for the three months ended September 30, 2025, and by $6.8 million, or 14%, to $54.3 million for the nine months ended September 30, 2025[140] - General and administrative expenses rose by $2.9 million, or 11%, to $29.2 million for the three months ended September 30, 2025, and by $11.5 million, or 15%, to $89.9 million for the nine months ended September 30, 2025[141] - The company incurred stock-based compensation expenses of $13,362,000 for the nine months ended September 30, 2025, compared to $9,660,000 for the same period in 2024, reflecting a 38.0% increase[24] Acquisitions and Goodwill - The Company acquired Medtech Concepts, LLC for approximately $15,274, consisting of $3,000 in cash, $2,274 in common stock, and future payments totaling $2,500 over four anniversaries[40] - The Company purchased Boston Brace International, Inc. for a total consideration of $21,535 in cash and $233 in common stock[46] - Goodwill increased from $93,844 at January 1, 2025, to $103,613 by September 30, 2025, after accounting for acquisitions and impairments[52] - The Company recorded an impairment charge of $1,874 for goodwill and $0.4 million for customer relationship intangible assets due to exiting the regulatory consulting business[55] Debt and Financing - As of September 30, 2025, total debt increased to $105,311 million from $77,483 million as of December 31, 2024, representing a 35.8% increase[65] - The Company issued $50,000 million in 4.75% Convertible Senior Notes due February 15, 2030, for an aggregate purchase price of $49,500 million[73] - The Company signed a $100 million term loan and private placement arrangement, consisting of a $50 million term loan and $50 million of convertible notes[153] - The term loan has an interest rate of SOFR + 6.50%, with payments being interest-only until maturity in August 2029[153] Market and Operational Insights - The company estimates the pediatric orthopedic market represents a $6.2 billion opportunity globally, including over $2.8 billion in the United States[122] - Revenue is typically higher in summer months and holiday periods due to increased pediatric surgeries[160] - The company operates approximately 40 orthotic and prosthetic clinics in the United States[123] - The company has expanded its international operations by establishing operating companies in the Netherlands and Germany in 2019 and 2022, respectively[126] Regulatory and Compliance - The company continues to evaluate the impact of recent accounting standards updates on its financial statements and disclosures[38] - Certifications of the Chief Executive Officer and Chief Financial Officer were filed in compliance with the Sarbanes-Oxley Act of 2002[193] - The company has committed to furnish omitted schedules from agreements to the SEC upon request[194]

Core Insights - Several biotech and healthcare stocks experienced significant after-hours trading gains due to clinical updates, strategic deals, and regulatory milestones [1] Company Summaries - **Genenta Science S.p.A. (GNTA)**: Shares closed at $2.40, down 27.71% during regular trading, but rebounded to $2.45, up 2.08% in after-hours. The volatility was driven by a $15 million registered direct offering and a strategic collaboration announcement [2] - **EDAP TMS S.A. (EDAP)**: Closed at $1.81, down 22.58%, but rose 8.29% to $1.96 in after-hours trading. The recovery appears technical, with no new news, and is supported by upcoming investor meetings at the UBS Global Healthcare Conference [3] - **BridgeBio Pharma Inc. (BBIO)**: Ended regular trading at $64.50, up 1.48%, and climbed 6.71% to $68.83 after hours. The increase reflects anticipation for Phase 3 CALIBRATE trial results for ADH1, with topline data expected on October 29 [4] - **OrthoPediatrics Corp. (KIDS)**: Closed at $16.91, down 0.29%, but surged 6.45% to $18.00 after releasing Q3 financial results, reporting a GAAP loss per share of $(0.50) despite 12% revenue growth [5][6] - The company raised its full-year 2025 revenue guidance to $233.5 million to $234.5 million, indicating projected growth of 14% to 15% compared to the prior year [7] - **Modular Medical Inc. (MODD)**: Dipped 1.30% to $0.5392 but rallied 5.38% to $0.5682 after hours following the successful completion of its Stage 1 ISO 13485:2016 audit, a key step toward CE Mark certification [8] - **Vivani Medical Inc. (VANI)**: Rose 3.09% to $1.67 and added 3.65% to $1.7310 after closing a $15.7 million capital raise, which included a registered direct offering and private placement, indicating insider confidence [9] - **Amarin Corp. plc (AMRN)**: Slipped 1.56% to $18.94 but rebounded 5.07% to $19.90 after the FDA revised fenofibrate drug labeling, which may favor Amarin's Vascepa in the lipid management space [10]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]